{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:14:33Z","timestamp":1791296073562,"version":"4.1.0"},"reference-count":14,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2017,9,15]]},"abstract":"<jats:p>For 30 years, Phelan and co-workers described a syndrome characterised by neonatal hypotonia, global developmental delay, strongly impaired speech, sleep disturbances and hyperreactivity to sensory stimuli. This Phelan-McDermid syndrome (PMS), also presenting with symptoms from the autism spectrum and a higher risk of developing seizure disorders, may be caused by a deletion of chromosome 22q13 or by a mutation in the<jats:italic>SHANK3<\/jats:italic>gene. Its core psychopathological phenotype comprises symptoms from the bipolar spectrum for which generally treatment with a mood-stabilising anticonvulsant in combination with an atypical antipsychotic seems to be most effective. In addition to two elsewhere published adolescent patients, we here describe in detail the history of an adult male patient with PMS caused by a<jats:italic>SHANK3<\/jats:italic>mutation in whom successive treatment regimens with antipsychotics and mood-stabilising anticonvulsants were all ineffective. Ultimately, addition of lithium to existing olanzapine therapy led to enduring stabilisation of mood and behaviour.<\/jats:p>","DOI":"10.1136\/bcr-2017-220778","type":"journal-article","created":{"date-parts":[[2017,9,28]],"date-time":"2017-09-28T15:35:18Z","timestamp":1506612918000},"page":"bcr-2017-220778","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":38,"title":["Phelan-McDermid syndrome due to<i>SHANK3<\/i>mutation in an intellectually disabled adult male: successful treatment with lithium"],"prefix":"10.1136","volume":"2017","author":[{"given":"Jos I M","family":"Egger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem M A","family":"Verhoeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renske","family":"Groenendijk-Reijenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina G","family":"Kant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,9,28]]},"reference":[{"key":"2025042712442755000_2017.sep27_3.bcr-2017-220778.1","first-page":"A118","article-title":"A de novo terminal deletion of 22q","volume":"43","author":"Phelan","year":"1988","journal-title":"Am J Hum Genet"},{"key":"2025042712442755000_2017.sep27_3.bcr-2017-220778.2","doi-asserted-by":"publisher","DOI":"10.1002\/1096-8628(20010615)101:2<91::AID-AJMG1340>3.0.CO;2-C"},{"key":"2025042712442755000_2017.sep27_3.bcr-2017-220778.3","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-3-14"},{"key":"2025042712442755000_2017.sep27_3.bcr-2017-220778.4","doi-asserted-by":"publisher","DOI":"10.1159\/000334260"},{"key":"2025042712442755000_2017.sep27_3.bcr-2017-220778.5","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0004.2000.570203.x"},{"key":"2025042712442755000_2017.sep27_3.bcr-2017-220778.6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ajmg.c.30155","article-title":"22q13.3 deletion syndrome: a recognizable malformation syndrome associated with marked speech and language delay","volume":"145C","author":"Cusmano-Ozog","year":"2007","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"2025042712442755000_2017.sep27_3.bcr-2017-220778.7","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s13311-015-0352-z","article-title":"Phelan-McDermid syndrome and SHANK3: implications for treatment","volume":"12","author":"Costales","year":"2015","journal-title":"Neurotherapeutics"},{"key":"2025042712442755000_2017.sep27_3.bcr-2017-220778.8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2147\/NDT.S30506","article-title":"Phelan-McDermid syndrome in two adult brothers: atypical bipolar disorder as its psychopathological phenotype?","volume":"8","author":"Verhoeven","year":"2012","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2025042712442755000_2017.sep27_3.bcr-2017-220778.9","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/ajmg.a.35597","article-title":"Phelan-McDermid syndrome: clinical report of a 70-year-old woman","volume":"161A","author":"Verhoeven","year":"2013","journal-title":"Am J Med Genet A"},{"key":"2025042712442755000_2017.sep27_3.bcr-2017-220778.10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000339119","article-title":"Neuropsychopathology in 7 patients with the 22q13 deletion syndrome: presence of bipolar disorder and progressive loss of skills","volume":"3","author":"Denayer","year":"2012","journal-title":"Mol Syndromol"},{"key":"2025042712442755000_2017.sep27_3.bcr-2017-220778.11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/gbb.12285","article-title":"Neuropsychological phenotype and psychopathology in seven adult patients with Phelan-McDermid syndrome: implications for treatment strategy","volume":"15","author":"Egger","year":"2016","journal-title":"Genes Brain Behav"},{"key":"2025042712442755000_2017.sep27_3.bcr-2017-220778.12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12888-015-0490-1","article-title":"Lithium as a rescue therapy for regression and catatonia features in two SHANK3 patients with autism spectrum disorder: case reports","volume":"15","author":"Serret","year":"2015","journal-title":"BMC Psychiatry"},{"key":"2025042712442755000_2017.sep27_3.bcr-2017-220778.13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ebiom.2016.05.032","article-title":"Human pluripotent stem cell-derived cortical neurons for high throughput medication screening in autism: a proof of concept study in SHANK3 haploinsufficiency syndrome","volume":"9","author":"Darville","year":"2016","journal-title":"EBioMedicine"},{"key":"2025042712442755000_2017.sep27_3.bcr-2017-220778.14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1021\/cn500077p","article-title":"Lithium: a promising treatment for fragile X syndrome","volume":"5","author":"Liu","year":"2014","journal-title":"ACS Chem Neurosci"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-220778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T19:44:33Z","timestamp":1745783073000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-220778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,28]]},"references-count":14,"alternative-id":["10.1136\/bcr-2017-220778"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-220778","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,28]]}}}